LYL-845 is under clinical development by Lyell Immunopharma and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LYL-845’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LYL-845 overview

LYL-845 is under development for the treatment of solid tumor, relapsed and refractory metastatic melanoma, relapsed and refractory non-small cell lung cancer and relapsed and refractory metastatic colorectal cancer. The therapeutic candidate comprises autologous, tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform.

Lyell Immunopharma overview

Lyell Immunopharma (Lyell) is a biotechnology company developing cell-based immunotherapies for solid tumors and other cancers. It provides effective cell therapy is the profound understanding of the identity, fate, and function of cells to create living medicines. The company focuses on controlling and improving the differentiation and functionality of T cells armed with TCRs (T-cell receptor), CARs (chimeric antigen receptor), and other targeting modalities. Lyell ‘s effective cell therapy is the deep and profound understanding of the identity, fate and function of cells to create living medicines. The company operates an office in Seattle, Washington, the US. Lyell is headquartered in South San Francisco, California, the US.

For a complete picture of LYL-845’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.